The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Anixa Biosciences. The maintained price target of $12 also indicates the firm's continued confidence in the company's potential. This could potentially lead to an increase in investor confidence and a short-term positive impact on the stock price.